The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) have published a draft agenda for a meeting of the European platform for regulatory science research, scheduled to take place on 9 June 2026. The meeting is intended to advance coordination on regulatory science research priorities across the European medicines network.
The draft agenda, published by EMA, lists discussions on ongoing research projects, methodological guidance, and potential areas for joint action. The platform brings together national competent authorities, EMA scientific committees, and academic partners to align research efforts that support regulatory decision-making.
No prior coverage of this specific meeting exists in recent months, making this the first public indication of the platform's work programme for the second half of 2026. The meeting is expected to produce recommendations for future regulatory science research topics, which could influence EMA's guidance development and the prioritisation of studies submitted in marketing authorisation applications.
Stakeholders likely to be impacted include pharmaceutical companies, which may see shifts in data requirements for new drug approvals; national medicines agencies, which will coordinate research activities; academic researchers, who may gain funding or collaboration opportunities; and patient organisations, which could benefit from more targeted evidence generation. The meeting's outcomes are not binding but may shape EMA's scientific advice and guideline development over the following year.
← Atlas › News › Health & Lifestyle